Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRAS | P01112 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980722 | 0.84 | OGA (0.35) | MAPK1 | |
| SCHEMBL30980721 | 0.73 | LGALS3 (0.49) | MAPK1ALDH1A1THRB | |
| SCHEMBL30980689 | 0.73 | LGALS3 (0.41) | MAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL10261426 | 0.72 | MAPK1 (0.65) | MAPK1MEN1KMT2ACD69ALDH1A1 | |
| SCHEMBL23618308 | 0.72 | MAPK1 (0.65) | MAPK1MEN1KMT2ACD69ALDH1A1 | |
| SCHEMBL24531188 | 0.72 | MAPK1 (0.65) | MAPK1MEN1KMT2ACD69ALDH1A1 | |
| SCHEMBL23133631 | 0.72 | MAPK1 (0.65) | MAPK1MEN1KMT2ACD69ALDH1A1 | |
| SCHEMBL2292636 | 0.72 | MAPK1 (0.65) | MAPK1MEN1KMT2ACD69ALDH1A1 | |
| SCHEMBL730739 | 0.72 | MAPK1 (0.65) | MAPK1MEN1KMT2ACD69ALDH1A1 | |
| SCHEMBL19935097 | 0.72 | MAPK1 (0.65) | MAPK1MEN1KMT2ACD69ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024155747-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |